LETTER TO EDITOR
Year : 2003 | Volume
: 51 | Issue : 2 | Page : 198--199
Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report.
P Parmar, A Salman
|How to cite this article:|
Parmar P, Salman A. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol 2003;51:198-199
|How to cite this URL:|
Parmar P, Salman A. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol [serial online] 2003 [cited 2020 Feb 26 ];51:198-199
Available from: http://www.ijo.in/text.asp?2003/51/2/198/14699
We read with interest the article by Mandal and associates on the use of mitomycin-C (MMC) augmented trabeculectomy for the management of neovascular glaucoma (NVG). We have also found that while the use of MMC augmented trabeculectomy for NVG is fairly widespread, published studies regarding this procedure are scarce. However, we disagree that there are no published reports about this technique. We are aware of at least two studies involving use of MMC in trabeculectomy for NVG that appear in the literature. Hyung and Kim studied MMC-augmented trabeculectomy in 24 eyes of 23 patients with NVG with a mean follow-up of 25.8 months (this article is indexed in MEDLINE). They found an average intraocular pressure (IOP) reduction of about 28.6 mmHg and a success rate of 71% at 1 month, which fell to 29% at 12 months. They conclude that this technique is successful in the treatment of NVG. Rao et al studied anterior retinal cryoablation prior to MMC augmented trabeculectomy in management of NVG. Chronic open angle glaucoma, chronic uveitis, proliferative diabetic retinopathy and ischaemic central retinal vein occlusion were the main causes of NVG. Of the 13 eyes undergoing surgery, IOP was controlled in 12 with a mean IOP reduction of 20 mmHg.
In addition, a clarification is required regarding the number of eyes that received previous retinal ablation in the present study. [Table 1] shows that 10 eyes (66.7%) received prior ablation while a look at [Table 2] shows that 13 eyes (86.7%) have received prior ablation.
|1||Mandal AK, Majji AB, Mandal SP, Das T, Jalali S, Gothwal VK, et al. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol 2002;50:287-93.|
|2||Hyung SM, Kim SK. Mid-term effects of trabeculectomy with mitomycin-C in neovascular glaucoma patients. Korean J Ophthalmol 2001;15:98-106.|
|3||Rao VA, Salman A, Parmar P, Babu N. Anterior retinal cryoablation in the management of neovascular glaucoma. Proceedings of All India Ophthalmological Conference 200;217:19.|